ANNOVIS BIO
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
ANNOVIS BIO
Industry:
Biotechnology Developer Platform Therapeutics
Founded:
2008-01-01
Address:
Berwyn, Pennsylvania, United States
Country:
United States
Website Url:
http://www.annovisbio.com
Total Employee:
1+
Status:
Active
Contact:
(610)727-3913
Email Addresses:
[email protected]
Total Funding:
58.98 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro GStatic Google Static Content Sectigo SSL Sectigo Domain SSL PostalAddress Schema
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Employees Featured
Founder
Stock Details
Investors List
Robin Hood Ventures
Robin Hood Ventures investment in Post-IPO Equity - Annovis Bio
Robin Hood Ventures
Robin Hood Ventures investment in Series A - Annovis Bio
Robin Hood Ventures
Robin Hood Ventures investment in Series A - Annovis Bio
Delaware Crossing Investor Group
Delaware Crossing Investor Group investment in Series A - Annovis Bio
Michael Hoffman
Michael Hoffman investment in Series A - Annovis Bio
Keiretsu Forum
Keiretsu Forum investment in Series A - Annovis Bio
BioAdvance
BioAdvance investment in Seed Round - Annovis Bio
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania investment in Seed Round - Annovis Bio
BioAdvance
BioAdvance investment in Debt Financing - Annovis Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-29 | Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer |
Official Site Inspections
http://www.annovisbio.com Semrush global rank: 4.5 M Semrush visits lastest month: 2.39 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Annovis Bio"
About Us - ANNOVIS BIO
Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. She was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel …See details»
Annovis Provides Corporate Updates and Reports Fourth Quarter …
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering …See details»
Annovis Provides Corporate Updates and Reports Fourth
2 days ago The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on …See details»
Annovis Bio - Crunchbase Company Profile & Funding
Annovis Bio raised $21 million through a public offering of 5,250,000 shares of common stock and warrants, which closed successfully. The proceeds from this offering were allocated to support …See details»
Annovis Bio, Inc. (ANVS) Company Profile & Facts - Yahoo Finance
See the company profile for Annovis Bio, Inc. (ANVS) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Annovis Bio, Inc. Announces Proposed Public Offering
Feb 1, 2025 For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X. Forward-Looking Statements:See details»
Annovis Bio, Inc. Announces Pricing of $21 Million Public
Feb 3, 2025 For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X. Forward Looking StatementsSee details»
Annovis Bio - Overview, News & Similar companies | ZoomInfo.com
May 21, 2024 View Annovis Bio (www.annovisbio.com) location in Pennsylvania, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Investor Relations - EQS Group
ANVS is an innovative company dedicated to advancing the treatment of neurodegenerative diseases by developing groundbreaking therapies that address Alzheimer's, Parkinson's, and …See details»
Annovis Bio - News, Locations, Executives and Competitors - Usearch
Feb 7, 2025 Usearch discovered 1 location for Annovis Bio including locations in Berwyn · Pennsylvania. Annovis Bio is headquartered in 101 Lindenwood Dr Ste 225. Usearch has …See details»
Annovis Bio Inc. Reports Corporate Updates and Financial
2 days ago Annovis Bio reports progress in neurodegenerative disease therapies, including positive trial results and financial updates for 2024. Quiver AI Summary Annovis Bio Inc., a …See details»
Annovis Bio - Craft
Oct 29, 2024 Annovis Bio has 2 employees at their 1 location. See insights on Annovis Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Annovis Bio Welcomes Four New Executives to Strengthen …
MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering …See details»
Annovis Granted U.S. Patent for Treatment and Prevention of …
Jan 14, 2025 For more information, visit www.annovisbio.comand follow us on LinkedIn, YouTube, and X. Investor AlertsSee details»
Annovis Granted U.S. Patent for Treatment and Prevention of
Jan 14, 2025 Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection January 14, 2025 08:00 ET | Source: Annovis Bio, Inc.See details»
Annovis Bio Reports Third Quarter Financial Results and Provides ...
Nov 11, 2024 For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.See details»
Press Release - annovisbio.com
Sep 5, 2024 Join the Annovis Bio Newsletter to receive the latest updates on our groundbreaking research and developments in neurodegenerative diseases like Alzheimer's …See details»
Annovis Bio Inc, ANVS:NYQ profile - FT.com
Mar 14, 2025 Annovis Bio Inc (ANVS:NYQ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Annovis Bio Reports Third Quarter Financial Results and Provides ...
MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel …See details»
Annovis Bio Reports Third Quarter Financial Results and
Nov 11, 2024 Annovis Bio Reports Third Quarter Financial Results and Provides Business Update November 11, 2024 08:00 ET | Source: Annovis Bio, Inc.See details»